AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
Log in

NASDAQ:AZRXAzurRx BioPharma Stock Price, Forecast & News

$0.84
-0.01 (-1.74 %)
(As of 07/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$0.83
Now: $0.84
$0.91
50-Day Range
$0.80
MA: $0.90
$1.02
52-Week Range
$0.37
Now: $0.84
$1.94
Volume76,100 shs
Average Volume377,021 shs
Market Capitalization$23.56 million
P/E RatioN/A
Dividend YieldN/A
Beta2.03
AzurRx BioPharma, Inc. researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea. The company was incorporated in 2014 and is headquartered in Brooklyn, New York.
Read More
AzurRx BioPharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.43 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AZRX
CUSIPN/A
Phone646-699-7855

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.17 per share

Profitability

Net Income$-15,180,000.00

Miscellaneous

Employees12
Market Cap$23.56 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive AZRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AZRX and its competitors with MarketBeat's FREE daily newsletter.

AzurRx BioPharma (NASDAQ:AZRX) Frequently Asked Questions

How has AzurRx BioPharma's stock been impacted by COVID-19 (Coronavirus)?

AzurRx BioPharma's stock was trading at $0.6150 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AZRX stock has increased by 35.8% and is now trading at $0.8353. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AzurRx BioPharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AzurRx BioPharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AzurRx BioPharma.

When is AzurRx BioPharma's next earnings date?

AzurRx BioPharma is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for AzurRx BioPharma.

How were AzurRx BioPharma's earnings last quarter?

AzurRx BioPharma Inc (NASDAQ:AZRX) announced its quarterly earnings data on Friday, May, 15th. The company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.11) by $0.09. View AzurRx BioPharma's earnings history.

What price target have analysts set for AZRX?

3 Wall Street analysts have issued 12 month price objectives for AzurRx BioPharma's shares. Their forecasts range from $2.00 to $3.00. On average, they expect AzurRx BioPharma's share price to reach $2.50 in the next year. This suggests a possible upside of 199.3% from the stock's current price. View analysts' price targets for AzurRx BioPharma.

Has AzurRx BioPharma been receiving favorable news coverage?

Media coverage about AZRX stock has been trending somewhat negative this week, according to InfoTrie. The research group identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AzurRx BioPharma earned a media sentiment score of -1.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View the latest news about AzurRx BioPharma.

Are investors shorting AzurRx BioPharma?

AzurRx BioPharma saw a increase in short interest during the month of June. As of June 15th, there was short interest totaling 145,500 shares, an increase of 95.6% from the May 31st total of 74,400 shares. Based on an average trading volume of 305,500 shares, the short-interest ratio is currently 0.5 days. Currently, 0.6% of the shares of the company are short sold. View AzurRx BioPharma's Current Options Chain.

Who are some of AzurRx BioPharma's key competitors?

What other stocks do shareholders of AzurRx BioPharma own?

Who are AzurRx BioPharma's key executives?

AzurRx BioPharma's management team includes the following people:
  • Mr. Johan M. Spoor, Pres, CEO & Director (Age 47)
  • Mr. Maged S. Shenouda M.B.A., R.Ph., R.Ph, MBA, CFO & Director (Age 55)
  • Mr. Daniel Dupret, Chief Scientific Officer (Age 63)
  • Dr. Mathieu Schué Ph.D., Head of Laboratory
  • Dr. James E. Pennington, Chief Medical Officer (Age 76)

When did AzurRx BioPharma IPO?

(AZRX) raised $15 million in an initial public offering on Friday, September 9th 2016. The company issued 2,100,000 shares at $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities acted as the underwriters for the IPO.

What is AzurRx BioPharma's stock symbol?

AzurRx BioPharma trades on the NASDAQ under the ticker symbol "AZRX."

How do I buy shares of AzurRx BioPharma?

Shares of AZRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AzurRx BioPharma's stock price today?

One share of AZRX stock can currently be purchased for approximately $0.84.

How big of a company is AzurRx BioPharma?

AzurRx BioPharma has a market capitalization of $23.56 million. AzurRx BioPharma employs 12 workers across the globe.

What is AzurRx BioPharma's official website?

The official website for AzurRx BioPharma is www.azurrx.com.

How can I contact AzurRx BioPharma?

AzurRx BioPharma's mailing address is 760 PARKSIDE AVENUE SUITE 304, BROOKLYN NY, 11226. The company can be reached via phone at 646-699-7855 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.